Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Want to cut your energy bills? Here’s how five experts are doing it 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Heidelberg, Germany, May 30, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 2:00 p.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
